Antitumor effect of apoptin-producing recombinant vaccinia virus strain in vivo is related with blockage of mitotic division in cancer cells

Zonov, E. V.; Кочнева, Г. В.; Tupitsyna, Anastasiya; Рябчикова, Е. И.

doi:10.18821/0208-0613-2016-34-4-154-159

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, quite a number of different transgenes have been explored to boost the action of OVs in Russia. For example, the apoptin gene from chicken anemia virus have been reported to improve oncolytic action of vaccinia virus [78][79][80]. A similar approach has been tested for adenoviruses [81].…”

Section: Genomic Engineering Of Ovsmentioning

confidence: 99%

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Nm¹,

Pestov²,

Jm³

et al. 2021

Preprint

View full text Add to dashboard Cite

The idea of using the lytic power of viruses against the malignant cells has been entertained for many decades. However, oncolytic viruses (OV) gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of the oncolytic herpesvirus to treat advanced melanoma. OVs offer an attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, yet the latter effect is less well studied. Nevertheless, OVs can be envisaged as potential in situ tumor vaccines. The therapeutic potential of OVs can be instigated further by using the molecular biological and biotechnological tools to modify the existing viruses for their optimal tumor selectivity and enhanced immune stimulation. Furthermore, OVs can be readily combined with other therapeutic agents to increase the efficacy of the existing therapeutic schemes. In this review, we discuss biotechnological advances in the development of therapeutic applications of OVs in Russia. Particular emphasis is made on the OV-mediated treatment of glioblastoma. In addition, we highlight the challenges of oncolytic virotherapy, and describe the strategies to optimize current approaches to improve clinical outcomes.

show abstract

Section: Genomic Engineering Of Ovsmentioning

confidence: 99%